Skip to main content
Premium Trial:

Request an Annual Quote

LexaGene Closes C$2.8M Private Placement

NEW YORK (GenomeWeb) — LexaGene said today that it has closed an oversubscribed private placement, grossing C$2.8 million ($2.1 million).

Through the transaction, Beverly, Massachusetts-based LexaGene — which trades on the Toronto Stock Exchange — sold roughly 4.4 million units consisting of one common share and one warrant for C$.65 apiece. Each warrant can be used to purchase a common share of the company for C$.85 and is exercisable over the next 15 months, subject to certain conditions that trigger an accelerated expiry.

LexaGene said it intends to use the proceeds of the transaction to fund beta development of its LX Analyzer technology, which uses microfluidic PCR for pathogen detection, and for marketing the technology to the food safety and veterinary diagnostics industries.

LexaGene announced plans for the private placement earlier this month. Last summer, the firm closed a bought deal financing to raise C$5.8 million.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.